Evidence map›Paper›PMID 39894499›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Unrelated Bone Marrow Transplantation for Chronic Myeloid Leukemia after Liver Transplantation.

Mirea Watanabe, Atsushi Marumo, Daishi Onai, Meya Li, Yuta Kaito, Toshio Asayama, Shunsuke Yui, Yasunobu Nagata, Satoshi Wakita, Hiroki Yamaguchi

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mirea WatanabeDepartment of Hematology, Nippon Medical School, Japan.
Atsushi MarumoDepartment of Hematology, Nippon Medical School, Japan.
Daishi OnaiDepartment of Hematology, Nippon Medical School, Japan.
Meya LiDepartment of Hematology, Nippon Medical School, Japan.
Yuta KaitoDepartment of Hematology, Nippon Medical School, Japan.
Toshio AsayamaDepartment of Hematology, Nippon Medical School, Japan.
Shunsuke YuiDepartment of Hematology, Nippon Medical School, Japan.
Yasunobu NagataDepartment of Hematology, Nippon Medical School, Japan.
Satoshi WakitaDepartment of Hematology, Nippon Medical School, Japan.
Hiroki YamaguchiDepartment of Hematology, Nippon Medical School, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report describes the case of a 29-year-old patient with chronic myeloid leukemia in the blast phase who underwent hematopoietic stem cell transplantation (HSCT) after living-donor liver transplantation. Donor selection, conditioning regimens, and graft-versus-host disease (GVHD) prophylaxis are discussed. The patient received a non-myeloablative conditioning regimen and ABO blood group-matched unrelated human leukocyte antigen fully-matched donors. Immunosuppressants tacrolimus and mycophenolate mofetil were administered to prevent GVHD. Maintenance therapy with ponatinib effectively maintained remission. This case highlights the complexities of managing HSCT after solid organ transplantation and suggests strategies for future cases.

Indexed as

Bone Marrow TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLiver TransplantationUnrelated DonorsAdultGraft vs Host DiseaseHematopoietic Stem Cell TransplantationHumansImidazolesImmunosuppressive AgentsMalePyridazinesTransplantation ConditioningImidazolesImmunosuppressive AgentsponatinibPyridazineschronic myeloid leukemiahematopoietic stem cell transplantationliver dysfunctionliver transplantationpost-transplant-related complications

Identifiers

PMID39894499
PMCPMC12393962

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.